Confirmed Control Announced Deal verified CPGMicrobiome SupplementsProbioticsProbiotics / Microbiome Supplements

Microbiome Labs acquired by Novozymes

Novozymes agreed to acquire Microbiome Labs, an US probiotics / microbiome supplements brand on Jan 6, 2021. The transaction value is shown as USD 125m. The current comp implies EV / revenue of 3.1x. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.

Transaction summary

Target
Microbiome Labs
Acquirer
Novozymes
Seller
-
Announced
2021-01-06
Geography
United States
Tags
CPGMicrobiome SupplementsProbioticsProbiotics / Microbiome Supplements
Type
Acquisition
Deal type
Control
Stake acquired
-
First added
2026-06-19
Latest update
2026-06-19

Value and multiples

Price / value

$125M

Consideration | USD

Basis: Public source

EV / revenue

3.1x

unknown

Basis: FundComb estimate

EV / EBITDA

6x

Basis: FundComb estimate

Basis

  • USD 125m consideration is treated as publicly disclosed or derived directly from public source data.
  • EV / revenue is shown as 3.1x based on the available comp inputs.
  • Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
  • EV / EBITDA is shown as 6x based on the available comp inputs.

Source summary

No public source summary has been published for this transaction yet.